P
US8614318B2ExpiredUtilityPatentIndex 92

Apoptosis promoters

Assignee: BRUNCKO MILANPriority: Nov 13, 2003Filed: Jul 24, 2006Granted: Dec 24, 2013
Est. expiryNov 13, 2023(expired)· nominal 20-yr term from priority
Inventors:BRUNCKO MILANDING HONGELMORE STEVENKUNZER AARONLYNCH CHRISTOPHER LMCCLELLAN WILLIAMPARK CHEOL-MINPETROS ANDREWSONG XIAOHONGWANG XILUTU NOAHWENDT MICHAELSHOEMAKER ALEXANDER RMITTEN MICHAEL J
C07D 487/08C07D 233/06C07D 403/12C07D 333/34C07D 213/70C07D 403/04C07D 487/04C07D 213/82C07D 295/30C07D 207/50C07D 401/10C07D 333/20C07D 211/46C07D 261/20C07D 267/10C07D 233/61C07D 211/72C07D 233/64C07D 211/48C07D 405/12C07D 239/38C07D 235/08C07D 309/14C07D 207/12C07D 211/34C07D 207/16C07D 207/20C07D 231/56C07D 211/20C07D 409/10C07D 491/04C07D 211/62C07D 231/12C07D 239/06C07D 213/42C07D 265/30C07D 211/14C07D 207/06C07D 213/74C07D 263/12C07D 471/08C07D 263/22C07D 207/24C07D 213/81C07D 277/36C07D 241/04C07D 277/74C07D 211/26C07D 401/12C07D 249/18C07D 335/02C07D 215/12C07D 307/22C07D 211/70C07D 211/58C07D 213/38C07D 295/155C07D 491/08C07D 498/08C07D 307/14C07D 413/04C07D 309/20C07D 205/04C07D 257/04C07D 307/81C07D 295/185C07D 213/36C07D 211/38C07D 273/01C07D 263/58C07D 211/42C07D 207/14C07D 317/66C07D 207/08
92
PatentIndex Score
37
Cited by
47
References
2
Claims

Abstract

Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A compound selected from the group consisting of:
 N-(6-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)-1,2-benzisoxazol-3-yl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide; 
 N-(6-(4-((4′-chloro(1,1-biphenyl)-2-yl)methyl)piperazin-1-yl)-1,2-benzisoxazol-3-yl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide; 
 N-(6-(4,4-dimethylpiperidin-1-yl)-1,2-benzisoxazol-3-yl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide; 
 N-(6-(4,4-dimethylpiperidin-1-yl)-1,2-benzisoxazol-3-yl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide; 
 N-(6-(4-(3,3-diphenylpropen-2-yl)piperazin-1-yl)-1,2-benzisoxazol-3-yl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide; 
 N-(6-(4-(3,3-diphenylpropen-2-yl)piperazin-1-yl)-1,2-benzisoxazol-3-yl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide; 
 N-(6-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)-1,2-benzisoxazol-3-yl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide; and 
 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(6-(4,4-dimethylpiperidin-1-yl)-1,2-benzisoxazol-3-yl)-3-nitrobenzenesulfonamide, or a therapeutically acceptable salt thereof. 
 
     
     
       2. A compound selected from the group consisting of:
 N-(6-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)-1-methyl-1H-indazol-3-yl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide; 
 N-(6-(4-((4-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)-1-methyl-1H-indazol-3-yl)-4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide; 
 N-(6-(4-((4′-chloro(1,1-biphenyl)-2-yl)methyl)piperazin-1-yl)-1-methyl-1H-indazol-3-yl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide; 
 N-(6-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)-1-methyl-1H-indazol-3-yl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzene sulfonamide; 
 N-(6-(4-((4′-chloro(1,1-biphenyl)-2-yl)methyl)piperazin-1-yl)-1H-indazol-3-yl)-3-nitro-4-((2-(phenyl sulfanyl)ethyl)amino)benzenesulfonamide; 
 N-(6-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)-1H-indazol-3-yl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide; and 
 N-(6-(4-((4-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)-1H-indazol-3-yl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)- amino)-3-nitrobenzenesulfonamide, or a therapeutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.